CYTK Cytokinetics, Incorporated Stock Quote

CYTK [NASD]

Index	-	P/E	-	EPS (ttm)	-1.91	Insider Own	1.00%	Shs Outstand	68.28M	Perf Week	-0.55%
Market Cap	1.47B	Forward P/E	-	EPS next Y	-1.98	Insider Trans	-48.42%	Shs Float	63.82M	Perf Month	-5.29%
Income	-114.00M	PEG	-	EPS next Q	-0.43	Inst Own	-	Short Float	14.58%	Perf Quarter	20.77%
Sales	54.30M	P/S	27.07	EPS this Y	-8.20%	Inst Trans	6.32%	Short Ratio	8.77	Perf Half Y	-20.88%
Book/sh	2.19	P/B	9.08	EPS next Y	-15.80%	ROA	-36.40%	Target Price	24.89	Perf Year	63.84%
Cash/sh	5.55	P/C	3.58	EPS next 5Y	15.00%	ROE	-	52W Range	8.00 - 30.14	Perf YTD	-4.28%
Dividend	-	P/FCF	-	EPS past 5Y	-38.80%	ROI	-83.50%	52W High	-33.58%	Beta	1.34
Dividend %	-	Quick Ratio	15.20	Sales past 5Y	-10.60%	Gross Margin	-	52W Low	150.25%	ATR	1.24
Employees	156	Current Ratio	15.20	Sales Q/Q	583.60%	Oper. Margin	-	RSI (14)	51.18	Volatility	5.11% 5.44%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	90.80%	Profit Margin	-	Rel Volume	0.80	Prev Close	19.89
Shortable	Yes	LT Debt/Eq	0.90	Earnings	Nov 04 AMC	Payout	-	Avg Volume	1.06M	Price	20.02
Recom	2.10	SMA20	-1.87%	SMA50	6.86%	SMA200	-1.05%	Volume	664,924	Change	0.65%

Jan-20-21

Reiterated

H.C. Wainwright

Buy

$22 → $41

Oct-29-20

Initiated

Goldman

Neutral

$16

Jul-10-20

Initiated

Raymond James

Strong Buy

$39

May-05-20

Initiated

Mizuho

Buy

$31

Apr-09-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$25

Sep-21-18

Initiated

Cantor Fitzgerald

Overweight

Sep-10-18

Resumed

Morgan Stanley

Equal-Weight

$10

Nov-22-17

Reiterated

Morgan Stanley

Overweight

$25 → $17

Nov-22-17

Downgrade

Needham

Strong Buy → Buy

$22 → $12

Nov-21-17

Reiterated

H.C. Wainwright

Buy

$26 → $17

Jul-31-17

Initiated

Morgan Stanley

Overweight

$24

Mar-08-17

Initiated

Rodman & Renshaw

Buy

$25

Feb-06-17

Upgrade

Needham

Buy → Strong Buy

$17 → $22

Dec-16-16

Initiated

Cantor Fitzgerald

Overweight

$21

Jul-28-16

Reiterated

Needham

Buy

$15 → $17

Nov-10-15

Reiterated

FBR Capital

Outperform

$14 → $24

Nov-09-15

Reiterated

ROTH Capital

Buy

$18 → $22

Jul-24-15

Reiterated

MLV & Co

Buy

$9 → $14

Dec-31-14

Reiterated

ROTH Capital

Buy

$13 → $18

Nov-04-14

Upgrade

MLV & Co

Hold → Buy

Jan-13-21 07:30AM	Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM GlobeNewswire
Jan-11-21 07:30AM	Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy GlobeNewswire -7.19%
Jan-06-21 04:00PM	Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference GlobeNewswire +7.19%
Dec-23-20 07:30AM	Cytokinetics Regains European Rights to Omecamtiv Mecarbil GlobeNewswire
Dec-19-20 02:44PM	10 Best Biotech Stocks to Invest In According To Billionaire Biotech Hedge Fund Insider Monkey
Dec-14-20 07:30AM	Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND GlobeNewswire
Dec-09-20 07:30AM	Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2 GlobeNewswire +22.87%
Dec-07-20 07:30AM	Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists GlobeNewswire
Dec-03-20 07:30AM	Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND GlobeNewswire
Dec-01-20 04:00PM	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
07:30AM	Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum GlobeNewswire
Nov-29-20 06:44AM	Top 10 Healthcare Stocks To Buy for the Future Insider Monkey
Nov-24-20 04:00PM	Cytokinetics to Participate in Upcoming Investor Conferences GlobeNewswire
03:07PM	Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate Zacks
Nov-23-20 07:30AM	Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen GlobeNewswire
Nov-20-20 07:30AM	Cytokinetics Names Nancy Wysenski to Board of Directors GlobeNewswire
Nov-16-20 07:30AM	Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020 GlobeNewswire -5.63%
07:30AM	Cytokinetics Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA Scientific Sessions 2020 GlobeNewswire
Nov-13-20 11:53AM	Cytokinetics heart failure drug succeeds but slightly higher death rate seen - study Reuters -5.06%
11:35AM	Cytokinetics heart failure drug succeeds but slightly higher death rate seen -study Reuters
11:35AM	Cytokinetics Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medicine GlobeNewswire
Nov-10-20 04:00PM	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-06-20 07:30AM	Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020 GlobeNewswire
06:13AM	Need To Know: Analysts Are Much More Bullish On Cytokinetics, Incorporated (NASDAQ:CYTK) Revenues Simply Wall St.
Nov-04-20 10:32PM	Cytokinetics Inc (CYTK) Q3 2020 Earnings Call Transcript Motley Fool +7.66%
05:15PM	Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:00PM	Cytokinetics Reports Third Quarter 2020 Financial Results GlobeNewswire
02:30PM	Cytokinetics, Inc. to Host Earnings Call ACCESSWIRE
Oct-28-20 12:33PM	Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for Zacks -6.00%
Oct-22-20 12:33PM	Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline Zacks
08:43AM	What Did Cytokinetics' (NASDAQ:CYTK) CEO Take Home Last Year? Simply Wall St.
Oct-21-20 04:00PM	Cytokinetics to Announce Third Quarter Results on November 4, 2020 GlobeNewswire
Oct-13-20 03:24PM	Cytokinetics Stock is Down, But Not Out, Says Analyst TipRanks +7.92%
Oct-09-20 12:46PM	Amgen Down on Unsatisfactory Heart Failure Drug Study Results Zacks
Oct-08-20 04:13PM	Amgen and Cytokinetics Stocks Slide After Heart Drug Trial Results Barrons.com -42.14%
04:11PM	Amgen, Cytokinetics Partnership Disappoints With Data On Heart Treatment Investor's Business Daily
10:14AM	Return On Capital Employed Overview: Cytokinetics Benzinga
08:30AM	Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure PR Newswire
08:30AM	Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure GlobeNewswire
Oct-05-20 04:26PM	Bristol Myers Squibb To Add To Heart Treatment Portfolio With $13.1 Billion Acquisition Investor's Business Daily +19.26%
04:00PM	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:48AM	Cytokinetics (CYTK) in Focus: Stock Moves 5.7% Higher Zacks
07:30AM	Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020 GlobeNewswire
Oct-02-20 07:30AM	Cytokinetics Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure GlobeNewswire +5.68%
Sep-28-20 05:25PM	Hedge Funds Keep Buying Cytokinetics, Inc. (CYTK) Insider Monkey
Sep-25-20 08:56AM	Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock? Zacks +6.61%
Sep-24-20 04:00PM	Cytokinetics Announces Data to Be Presented at the HFSA Virtual Annual Scientific Meeting 2020 GlobeNewswire
07:30AM	Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals GlobeNewswire
Sep-23-20 07:30AM	Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271 GlobeNewswire
Sep-17-20 07:30AM	Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions GlobeNewswire
Sep-02-20 04:00PM	Cytokinetics to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-26-20 07:30AM	Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA GlobeNewswire
Aug-18-20 07:30AM	Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy GlobeNewswire
Aug-06-20 04:00PM	Cytokinetics Reports Second Quarter 2020 Financial Results GlobeNewswire
Jul-30-20 12:33PM	Earnings Preview: Cytokinetics (CYTK) Q2 Earnings Expected to Decline Zacks
Jul-24-20 08:36AM	Can You Imagine How Jubilant Cytokinetics' (NASDAQ:CYTK) Shareholders Feel About Its 279% Share Price Gain? Simply Wall St.
Jul-23-20 04:00PM	Cytokinetics to Announce Second Quarter Results on August 6, 2020 GlobeNewswire
Jul-21-20 04:00PM	Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -5.05%
04:00PM	Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-20-20 06:39PM	Did Hedge Funds Make The Right Call On Cytokinetics, Inc. (CYTK) ? Insider Monkey
Jul-16-20 11:32PM	Cytokinetics Announces Pricing of Public Offering of Common Stock GlobeNewswire -11.19%
08:31AM	The Daily Biotech Pulse: Mallinckrodt Gets FDA Panel Backing, Regulatory Setback For Tricida, Relay Therapeutics IPO Benzinga
Jul-15-20 04:00PM	Cytokinetics Announces Proposed Public Offering of Common Stock GlobeNewswire
07:30AM	Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Todays Virtual Investor & Analyst Day GlobeNewswire
Jul-14-20 07:30AM	Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor GlobeNewswire +16.07%
Jul-13-20 07:30AM	Cytokinetics Announces Participation in the Launch of Kainomyx, Inc. Focused to the Treatment of Parasitic Diseases GlobeNewswire -5.80%
Jul-10-20 10:10AM	Benzinga's Top Upgrades, Downgrades For July 10, 2020 Benzinga
Jul-01-20 04:00PM	Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020 GlobeNewswire
Jun-30-20 11:45AM	Cutting Edge Biotech Cytokinetics Could Double in Price TheStreet.com
Jun-16-20 09:48PM	Hedge Funds Have Never Been This Bullish On Cytokinetics, Inc. (CYTK) Insider Monkey
Jun-08-20 04:00PM	Cytokinetics to Participate In Upcoming Investor Conferences GlobeNewswire
Jun-04-20 11:35AM	Edited Transcript of CYTK earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-27-20 07:30AM	Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS GlobeNewswire
May-11-20 12:21PM	Here's Why Cytokinetics Is Skyrocketing 24.5% Today Motley Fool +33.23%
May-08-20 08:30AM	FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure GlobeNewswire
08:30AM	FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure PR Newswire
May-07-20 04:00PM	Cytokinetics Inc (CYTK) Q1 2020 Earnings Call Transcript Motley Fool -5.41%
04:00PM	Cytokinetics to Hold Annual Meeting of Stockholders GlobeNewswire
May-06-20 04:00PM	Cytokinetics Reports First Quarter 2020 Financial Results GlobeNewswire
May-05-20 11:46AM	3 Biotech Stocks With Plenty of Upside in the Pipeline TipRanks +8.24%
May-04-20 05:59PM	Cytokinetics Trading at Half High Target of $30 GuruFocus.com
07:58AM	Is Cytokinetics, Incorporated (NASDAQ:CYTK) Excessively Paying Its CEO? Simply Wall St.
Apr-30-20 08:33AM	3 Monster Growth Stocks With Still Plenty of Gas in the Tank TipRanks -7.19%
Apr-29-20 12:34PM	Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Apr-22-20 04:00PM	Cytokinetics to Announce First Quarter Results on May 6, 2020 GlobeNewswire
Apr-14-20 07:30AM	Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic GlobeNewswire
Apr-08-20 04:00PM	Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference GlobeNewswire +5.02%
Apr-01-20 07:32AM	Edited Transcript of CYTK earnings conference call or presentation 3-Mar-20 9:30pm GMT Thomson Reuters StreetEvents -5.43%
Mar-30-20 01:35PM	Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual GlobeNewswire +8.85%
07:30AM	Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual GlobeNewswire
Mar-20-20 04:00PM	CYTOKINETICS TO ANNOUNCE BASELINE CHARACTERISTICS FROM GALACTIC-HF DURING ACC.20/WCC GlobeNewswire +6.11%
Mar-04-20 07:30AM	Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis GlobeNewswire
Mar-03-20 05:15PM	Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:00PM	Cytokinetics Reports Fourth Quarter 2019 Financial Results GlobeNewswire
07:30AM	Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure GlobeNewswire
Feb-28-20 07:30AM	Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day GlobeNewswire
Feb-26-20 08:30AM	Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis GlobeNewswire
08:30AM	Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis PR Newswire
Feb-25-20 12:30PM	Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-20-20 07:30AM	Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting GlobeNewswire

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Malik Fady Ibraham	EVP Research & Development	Jan 14	Option Exercise	9.42	12,500	117,750	162,324	Jan 15 04:35 PM
Malik Fady Ibraham	EVP Research & Development	Jan 14	Sale	19.25	12,500	240,619	150,441	Jan 15 04:35 PM
Blum Robert I	President & CEO	Jan 04	Option Exercise	6.00	5,000	30,000	310,589	Jan 04 05:18 PM
Blum Robert I	President & CEO	Jan 04	Sale	20.23	5,000	101,135	305,589	Jan 04 05:18 PM
HENDERSON JOHN T	Director	Dec 31	Option Exercise	12.96	858	11,120	1,757	Dec 31 04:55 PM
HENDERSON JOHN T	Director	Dec 31	Sale	20.31	858	17,426	899	Dec 31 04:55 PM
Blum Robert I	President & CEO	Dec 16	Option Exercise	6.00	5,000	30,000	310,589	Dec 18 04:20 PM
Blum Robert I	President & CEO	Dec 16	Sale	20.51	5,000	102,551	305,589	Dec 18 04:20 PM
GAGE L PATRICK	Director	Dec 15	Option Exercise	12.96	7,716	99,999	28,520	Dec 15 06:09 PM
Cragg David	SVP Human Resources	Dec 15	Option Exercise	9.42	16,666	156,994	152,137	Dec 17 06:05 PM
GAGE L PATRICK	Director	Dec 15	Sale	21.00	7,716	162,038	20,804	Dec 15 06:09 PM
Malik Fady Ibraham	EVP Research & Development	Dec 10	Sale	20.13	1,052	21,177	150,441	Dec 10 05:06 PM
BVF PARTNERS L P/IL	See Explanaton of Responses	Dec 09	Sale	18.00	430,954	7,757,172	463,244	Dec 11 06:48 PM
Blum Robert I	President & CEO	Dec 04	Option Exercise	6.00	5,000	30,000	310,589	Dec 04 05:58 PM
Blum Robert I	President & CEO	Dec 04	Sale	17.36	5,000	86,799	305,589	Dec 04 05:58 PM
Blum Robert I	President & CEO	Nov 23	Option Exercise	6.00	5,000	30,000	309,868	Nov 25 04:20 PM
Blum Robert I	President & CEO	Nov 23	Sale	15.73	5,000	78,644	304,868	Nov 25 04:20 PM
Malik Fady Ibraham	EVP Research & Development	Nov 12	Sale	17.15	1,231	21,112	150,951	Nov 16 04:48 PM
Blum Robert I	President & CEO	Nov 10	Option Exercise	6.00	5,000	30,000	309,868	Nov 12 04:59 PM
Blum Robert I	President & CEO	Nov 10	Sale	16.50	5,000	82,488	304,868	Nov 12 04:59 PM
Blum Robert I	President & CEO	Oct 29	Option Exercise	6.00	5,000	30,000	309,868	Oct 30 04:50 PM
Blum Robert I	President & CEO	Oct 29	Sale	15.15	5,000	75,773	304,868	Oct 30 04:50 PM
Blum Robert I	President & CEO	Oct 13	Option Exercise	6.00	5,000	30,000	309,868	Oct 14 04:53 PM
Blum Robert I	President & CEO	Oct 13	Sale	15.94	5,000	79,686	304,868	Oct 14 04:53 PM
Malik Fady Ibraham	EVP Research & Development	Oct 08	Sale	17.45	1,258	21,952	152,182	Oct 08 05:08 PM
COSTA SANTO J	Director	Oct 05	Option Exercise	9.45	15,000	141,750	15,000	Oct 05 05:53 PM
Jaw Ching	SVP Finance & CFO	Oct 05	Option Exercise	10.03	27,500	275,700	88,300	Oct 05 08:23 PM
Kaye Edward M. MD	Director	Oct 05	Option Exercise	7.61	20,000	152,200	20,000	Oct 05 08:38 PM
HENDERSON JOHN T	Director	Oct 05	Option Exercise	12.96	3,000	38,880	2,399	Oct 05 09:03 PM
SMITH SANDFORD D	Director	Oct 05	Option Exercise	7.37	5,936	43,748	5,936	Oct 05 09:11 PM
PARSHALL B LYNNE	Director	Oct 05	Option Exercise	7.23	50,311	363,898	20,000	Oct 06 04:58 PM
PARSHALL B LYNNE	Director	Oct 05	Sale	30.00	50,311	1,509,330	0	Oct 06 04:58 PM
SMITH SANDFORD D	Director	Oct 05	Sale	30.00	5,936	178,080	0	Oct 05 09:11 PM
HENDERSON JOHN T	Director	Oct 05	Sale	29.00	3,000	87,000	899	Oct 05 09:03 PM
Kaye Edward M. MD	Director	Oct 05	Sale	30.00	20,000	600,000	0	Oct 05 08:38 PM
Jaw Ching	SVP Finance & CFO	Oct 05	Sale	30.00	27,500	825,000	73,300	Oct 05 08:23 PM
COSTA SANTO J	Director	Oct 05	Sale	30.00	15,000	450,000	0	Oct 05 05:53 PM
Blum Robert I	President & CEO	Oct 02	Option Exercise	6.00	5,000	30,000	309,868	Oct 02 05:48 PM
Blum Robert I	President & CEO	Oct 02	Sale	22.53	5,000	112,646	304,868	Oct 02 05:48 PM
Blum Robert I	President & CEO	Sep 21	Option Exercise	6.00	5,000	30,000	309,868	Sep 21 05:16 PM
Blum Robert I	President & CEO	Sep 21	Sale	20.97	5,000	104,835	304,868	Sep 21 05:16 PM
Blum Robert I	President & CEO	Sep 11	Option Exercise	6.00	5,000	30,000	309,868	Sep 11 05:05 PM
Blum Robert I	President & CEO	Sep 11	Sale	22.95	5,000	114,736	304,868	Sep 11 05:05 PM
Malik Fady Ibraham	EVP Research & Development	Sep 10	Sale	22.85	995	22,736	153,440	Sep 11 04:37 PM
Blum Robert I	President & CEO	Sep 04	Option Exercise	6.00	5,000	30,000	309,868	Sep 04 05:29 PM
Blum Robert I	President & CEO	Sep 04	Sale	22.37	5,000	111,855	304,868	Sep 04 05:29 PM
SCHLOSSBERG MARK A	SVP - Legal & General Counsel	Aug 21	Option Exercise	7.03	10,000	70,300	40,000	Aug 21 05:34 PM
Jaw Ching	SVP Finance & CFO	Aug 21	Option Exercise	7.54	25,000	188,400	88,300	Aug 21 05:41 PM
Jaw Ching	SVP Finance & CFO	Aug 21	Sale	25.00	25,000	625,000	73,300	Aug 21 05:41 PM
SCHLOSSBERG MARK A	SVP - Legal & General Counsel	Aug 21	Sale	25.00	10,000	250,000	30,000	Aug 21 05:34 PM
Blum Robert I	President & CEO	Aug 18	Option Exercise	6.00	5,000	30,000	309,868	Aug 20 04:27 PM
Blum Robert I	President & CEO	Aug 18	Sale	23.48	5,000	117,422	304,868	Aug 20 04:27 PM
Malik Fady Ibraham	EVP Research & Development	Aug 13	Sale	21.85	599	13,088	154,435	Aug 14 05:16 PM
Blum Robert I	President & CEO	Aug 05	Option Exercise	6.00	5,000	30,000	309,868	Aug 07 04:39 PM
Blum Robert I	President & CEO	Aug 05	Sale	22.12	5,000	110,621	304,868	Aug 07 04:39 PM
SCHLOSSBERG MARK A	SVP - Legal & General Counsel	Jul 29	Option Exercise	7.03	10,000	70,300	40,000	Jul 30 07:57 PM
SCHLOSSBERG MARK A	SVP - Legal & General Counsel	Jul 29	Sale	23.07	10,000	230,728	30,000	Jul 30 07:57 PM
Blum Robert I	President & CEO	Jul 28	Option Exercise	6.00	5,000	30,000	309,868	Jul 30 07:56 PM
Blum Robert I	President & CEO	Jul 28	Sale	23.77	5,000	118,829	304,868	Jul 30 07:56 PM
Blum Robert I	President & CEO	Jul 16	Option Exercise	6.00	5,000	30,000	309,868	Jul 17 05:15 PM
Blum Robert I	President & CEO	Jul 16	Sale	27.36	5,000	136,806	304,868	Jul 17 05:15 PM
SMITH SANDFORD D	Director	Jul 15	Option Exercise	6.21	6,667	41,402	6,667	Jul 17 05:14 PM
SMITH SANDFORD D	Director	Jul 15	Sale	29.00	6,667	193,343	0	Jul 17 05:14 PM
SMITH SANDFORD D	Director	Jul 10	Option Exercise	6.21	6,667	41,402	6,667	Jul 13 05:34 PM
SMITH SANDFORD D	Director	Jul 10	Sale	28.00	6,667	186,676	0	Jul 13 05:34 PM
Malik Fady Ibraham	EVP Research & Development	Jul 09	Sale	26.96	1,587	42,786	155,034	Jul 10 08:09 PM
SMITH SANDFORD D	Director	Jul 08	Option Exercise	6.21	1,434	8,905	1,434	Jul 09 05:37 PM
SMITH SANDFORD D	Director	Jul 08	Sale	27.00	1,434	38,718	0	Jul 09 05:37 PM
SMITH SANDFORD D	Director	Jul 07	Option Exercise	6.49	11,742	76,238	6,510	Jul 09 05:37 PM
SMITH SANDFORD D	Director	Jul 07	Sale	26.45	11,742	310,524	0	Jul 09 05:37 PM
Blum Robert I	President & CEO	Jul 06	Option Exercise	6.00	5,000	30,000	309,868	Jul 08 05:08 PM
Blum Robert I	President & CEO	Jul 06	Sale	24.85	5,000	124,255	304,868	Jul 08 05:08 PM
Blum Robert I	President & CEO	Jun 24	Option Exercise	6.07	5,000	30,354	308,689	Jun 26 04:41 PM
Blum Robert I	President & CEO	Jun 24	Sale	23.86	5,000	119,309	304,868	Jun 26 04:41 PM
SMITH SANDFORD D	Director	Jun 22	Option Exercise	4.44	10,000	44,400	5,000	Jun 22 05:43 PM
PARSHALL B LYNNE	Director	Jun 22	Option Exercise	5.34	16,510	88,147	10,000	Jun 23 05:00 PM
COSTA SANTO J	Director	Jun 22	Option Exercise	7.61	20,000	152,200	20,000	Jun 24 05:40 PM
COSTA SANTO J	Director	Jun 22	Sale	25.00	20,000	500,000	0	Jun 24 05:40 PM
PARSHALL B LYNNE	Director	Jun 22	Sale	25.00	16,510	412,750	0	Jun 23 05:00 PM
SMITH SANDFORD D	Director	Jun 22	Sale	24.50	10,000	245,000	0	Jun 22 05:43 PM
SMITH SANDFORD D	Director	Jun 17	Option Exercise	6.80	6,907	46,994	4,166	Jun 17 06:07 PM
SMITH SANDFORD D	Director	Jun 17	Sale	23.00	6,907	158,861	0	Jun 17 06:07 PM
SMITH SANDFORD D	Director	Jun 15	Option Exercise	6.30	6,666	41,996	6,666	Jun 15 05:57 PM
SMITH SANDFORD D	Director	Jun 15	Sale	22.00	6,666	146,652	0	Jun 15 05:57 PM
SMITH SANDFORD D	Director	Jun 12	Option Exercise	4.42	15,045	66,480	10,879	Jun 12 06:31 PM
SMITH SANDFORD D	Director	Jun 12	Sale	20.86	15,045	313,907	0	Jun 12 06:31 PM
Blum Robert I	President & CEO	Jun 11	Option Exercise	6.30	5,000	31,500	309,868	Jun 12 06:32 PM
Blum Robert I	President & CEO	Jun 11	Sale	21.47	5,000	107,354	304,868	Jun 12 06:32 PM
Blum Robert I	President & CEO	May 29	Option Exercise	6.30	5,000	31,500	308,633	May 29 07:45 PM
Blum Robert I	President & CEO	May 29	Sale	20.10	5,000	100,503	303,633	May 29 07:45 PM
HENDERSON JOHN T	Director	May 19	Option Exercise	16.86	3,333	56,194	3,583	May 20 05:04 PM
Blum Robert I	President & CEO	May 18	Option Exercise	6.30	4,189	26,391	307,822	May 18 07:37 PM
GAGE L PATRICK	Director	May 18	Option Exercise	16.86	3,333	56,194	23,333	May 20 05:04 PM
Blum Robert I	President & CEO	May 18	Sale	22.15	5,000	110,732	303,633	May 18 07:37 PM
COSTA SANTO J	Director	May 11	Option Exercise	8.49	29,999	254,587	20,000	May 12 04:22 PM
COSTA SANTO J	Director	May 11	Sale	19.82	29,999	594,687	0	May 12 04:22 PM
COSTA SANTO J	Director	May 05	Option Exercise	6.12	8,332	50,992	4,166	May 06 06:39 PM
COSTA SANTO J	Director	May 05	Sale	17.00	8,332	141,644	0	May 06 06:39 PM
Blum Robert I	President & CEO	May 01	Sale	14.34	5,000	71,678	304,444	May 01 07:06 PM
WIERENGA WENDALL	Director	Apr 28	Option Exercise	10.24	9,999	102,390	6,666	Apr 29 06:25 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience